Study title: Boenig, H., Silbermann, S., Weller, S., et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF): Results of a prospective randomised monocentre study Bone Marrow Transplantation 28(3): 259-264.Boenig, H., Silbermann, S., Weller, S., et al. Glycosylated vs non-glycosylated granulocyte colony-stimulating factor (G-CSF): Results of a prospective randomised monocentre study Bone Marrow Transplantation 28(3): 259-264.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Immune System Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: FILGASTRIM | |||||
| ATC code: L03AA02 | |||||
| Document link: Bibliography - Neupogen[2].pdf | |||||
| Document date: 2011-08-03 | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |